120 related articles for article (PubMed ID: 26841902)
1. A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
McWhirter E; Quirt I; Gajewski T; Pond G; Wang L; Hui J; Oza A
Invest New Drugs; 2016 Apr; 34(2):231-5. PubMed ID: 26841902
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Hirte H; Lheureux S; Fleming GF; Sugimoto A; Morgan R; Biagi J; Wang L; McGill S; Ivy SP; Oza AM
Gynecol Oncol; 2015 Jul; 138(1):55-61. PubMed ID: 25895616
[TBL] [Abstract][Full Text] [Related]
3. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
[TBL] [Abstract][Full Text] [Related]
5. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
Sridhar SS; Mackenzie MJ; Hotte SJ; Mukherjee SD; Tannock IF; Murray N; Kollmannsberger C; Haider MA; Chen EX; Halford R; Wang L; Ivy SP; Moore MJ
Invest New Drugs; 2013 Aug; 31(4):1008-15. PubMed ID: 23354849
[TBL] [Abstract][Full Text] [Related]
7. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Langenberg MH; van Herpen CM; De Bono J; Schellens JH; Unger C; Hoekman K; Blum HE; Fiedler W; Drevs J; Le Maulf F; Fielding A; Robertson J; Voest EE
J Clin Oncol; 2009 Dec; 27(36):6152-9. PubMed ID: 19901116
[TBL] [Abstract][Full Text] [Related]
8. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Campbell NP; Kunnavakkam R; Leighl N; Vincent MD; Gandara DR; Koczywas M; Gitlitz BJ; Agamah E; Thomas SP; Stadler WM; Vokes EE; Kindler HL
Lung Cancer; 2012 Oct; 78(1):76-80. PubMed ID: 22831987
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Ramalingam SS; Belani CP; Mack PC; Vokes EE; Longmate J; Govindan R; Koczywas M; Ivy SP; Gandara DR
J Thorac Oncol; 2010 Aug; 5(8):1279-84. PubMed ID: 20559150
[TBL] [Abstract][Full Text] [Related]
10. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Bender D; Sill MW; Lankes HA; Reyes HD; Darus CJ; Delmore JE; Rotmensch J; Gray HJ; Mannel RS; Schilder JM; Hunter MI; McCourt CK; Samuelson MI; Leslie KK
Gynecol Oncol; 2015 Sep; 138(3):507-12. PubMed ID: 26186911
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.
Chen E; Jonker D; Gauthier I; MacLean M; Wells J; Powers J; Seymour L
Clin Cancer Res; 2009 Feb; 15(4):1481-6. PubMed ID: 19228749
[TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
van Cruijsen H; Voest EE; Punt CJ; Hoekman K; Witteveen PO; Meijerink MR; Puchalski TA; Robertson J; Saunders O; Jürgensmeier JM; van Herpen CM; Giaccone G
Eur J Cancer; 2010 Mar; 46(5):901-11. PubMed ID: 20061136
[TBL] [Abstract][Full Text] [Related]
13. Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Brown N; McBain C; Nash S; Hopkins K; Sanghera P; Saran F; Phillips M; Dungey F; Clifton-Hadley L; Wanek K; Krell D; Jeffries S; Khan I; Smith P; Mulholland P
PLoS One; 2016; 11(5):e0156369. PubMed ID: 27232884
[TBL] [Abstract][Full Text] [Related]
14. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
Mulders P; Hawkins R; Nathan P; de Jong I; Osanto S; Porfiri E; Protheroe A; van Herpen CM; Mookerjee B; Pike L; Jürgensmeier JM; Gore ME
Eur J Cancer; 2012 Mar; 48(4):527-37. PubMed ID: 22285180
[TBL] [Abstract][Full Text] [Related]
15. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Trarbach T; Schultheis B; Gauler TC; Schneider V; Strumberg D; Eberhardt WE; Le Scouiller S; Marotti M; Brown KH; Drevs J
Invest New Drugs; 2012 Oct; 30(5):1962-71. PubMed ID: 21989836
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
Garland LL; Chansky K; Wozniak AJ; Tsao AS; Gadgeel SM; Verschraegen CF; Dasilva MA; Redman M; Gandara DR
J Thorac Oncol; 2011 Nov; 6(11):1938-45. PubMed ID: 21964533
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
Zhou C; Taylor S; Tugwood J; Simpson K; Jayson GC; Symonds P; Paul J; Davidson S; Carty K; McCartney E; Rai D; Dive C; West C
Br J Clin Pharmacol; 2019 Aug; 85(8):1781-1789. PubMed ID: 30980733
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Hubbard JM; Yin J; Schenk EL; Qin R; Reid JM; Strand C; Fiskum J; Menefee M; Lin G; Doyle LA; Ivy P; Erlichman C; Adjei A; Haluska P; Costello BA
Invest New Drugs; 2022 Feb; 40(1):115-123. PubMed ID: 34515877
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of gefitinib in patients with metastatic melanoma.
Patel SP; Kim KB; Papadopoulos NE; Hwu WJ; Hwu P; Prieto VG; Bar-Eli M; Zigler M; Dobroff A; Bronstein Y; Bassett RL; Vardeleon AG; Bedikian AY
Melanoma Res; 2011 Aug; 21(4):357-63. PubMed ID: 21738104
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE; Kane MA; List MA; Brockstein BE; Mehrotra B; Huo D; Mauer AM; Pierce C; Dekker A; Vokes EE
Clin Cancer Res; 2005 Dec; 11(23):8418-24. PubMed ID: 16322304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
